Jul 14
|
Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.
|
Jul 14
|
Tylenol parent Kenvue has a new CEO, and he has lots of work to do to mollify activist investors
|
Jul 14
|
Pre-Markets in the Red to Start a Fresh Week
|
Jul 14
|
Big Week of Inflation Data, Q2 Earnings Reports
|
Jul 14
|
Zimmer to acquire Monogram Technologies for $177 million, boosting robotics portfolio
|
Jul 14
|
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
|
Jul 14
|
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
|
Jul 14
|
Kenvue CEO Departs As Company Launches Strategic Review
|
Jul 14
|
Kenvue CEO Mongon leaves the consumer health company as it continues its strategic review
|
Jul 14
|
Stocks Decline Pre-Bell Amid Tariff Tensions; Investors Await Inflation Data, Earnings
|
Jul 6
|
J.P. Morgan Maintained Their Hold Rating on Johnson & Johnson (JNJ)
|
Jul 4
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
Jul 4
|
North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE
|
Jul 4
|
Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds
|
Jul 3
|
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
|
Jul 3
|
The Zacks Analyst Blog Highlights Johnson & Johnson, The Home Depot, Micron Technology, Autoscope Technologies and Nova LifeStyle
|
Jul 3
|
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
|
Jul 3
|
Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer ...
|
Jul 3
|
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
|
Jul 3
|
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
|